Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on June 26, 2018. The report details the entry into a material definitive agreement for a public offering of common stock and the commencement of trading on the Nasdaq Capital Market.
Key Financial Metrics
- Offering Size: 11,688,000 shares of common stock.
- Offering Price: $3.85 per share.
- Underwriter Option: 30-day option to purchase up to 1,753,200 additional shares.
- Expected Net Proceeds: Approximately $41.8 million (after underwriting discounts and estimated expenses).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of an underwriting agreement with Guggenheim Securities, LLC, to raise capital. Additionally, the company's common stock commenced trading on the Nasdaq Capital Market on June 26, 2018.
Guidance, Outlook, and Risks
Outlook: The closing of the offering is expected to occur on or about June 28, 2018, subject to customary closing conditions. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text.
Risks and Contingencies: The filing notes that the Underwriting Agreement contains customary representations, warranties, and termination provisions. It explicitly states that the agreement is not intended to provide factual information about the company beyond the terms of the offering.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 28, 2018).
- Confirm whether the underwriters exercised the 30-day option to purchase additional shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Check subsequent filings for the actual use of the $41.8 million in net proceeds.
- Confirm the company's current cash position and burn rate to assess runway extension.